Q-omics provides the consensus-scored PRPF18 profile across patient tissues and cancer cell-line models. PRPF18 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRPF18 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, PRPF18 RNA expression shows 19,168 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where PRPF18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRPF18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRPF18 survival associations across molecular data types. PRPF18 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRPF18 RNA expression–survival associations across cancer types. High PRPF18 expression shows unfavorable associations in SCLC, CESC, ACC and LIHC, but favorable associations in KIRC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRPF18 RNA expression.
This table summarizes PRPF18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PRPF18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRPF18 shows lower tumor expression in KICH and COAD and higher tumor expression in LIHC, STAD, HNSC and CHOL. The LIHC box plot shows higher PRPF18 RNA expression in tumor versus normal tissue (log2 FC = +0.709, t-test p < 0.001).
This table shows molecular features associated with PRPF18 in patient tissues and cancer cell lines. In patient samples, PRPF18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRPF18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
